<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20241010181013&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20241010181013&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 10 Oct 2024 22:10:13 +0000</lastbuilddate>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>β-blockers after MI: does ABYSS confirm REDUCEd use after all?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 9. doi: 10.1038/s41569-024-01093-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39384949</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01093-z>10.1038/s41569-024-01093-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384949</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>β-blockers after MI: does ABYSS confirm REDUCEd use after all?</dc:title>
<dc:identifier>pmid:39384949</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01093-z</dc:identifier>
</item>
<item>
<title>Tribute to an Outstanding Clinician and Friend Roman DeSanctis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384266/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1582-1583. doi: 10.1016/j.jacc.2024.08.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384266/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39384266</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.020>10.1016/j.jacc.2024.08.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384266</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tribute to an Outstanding Clinician and Friend Roman DeSanctis</dc:title>
<dc:identifier>pmid:39384266</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.020</dc:identifier>
</item>
<item>
<title>Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1578-1581. doi: 10.1016/j.jacc.2024.07.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39384265</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.036>10.1016/j.jacc.2024.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384265</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sungho Bea</dc:creator>
<dc:creator>Krista F Huybrechts</dc:creator>
<dc:creator>Heba H Edrees</dc:creator>
<dc:creator>C Andrew Basham</dc:creator>
<dc:creator>Seanna M Vine</dc:creator>
<dc:creator>Robert J Glynn</dc:creator>
<dc:creator>Brian T Bateman</dc:creator>
<dc:creator>Katsiaryna Bykov</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents</dc:title>
<dc:identifier>pmid:39384265</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.036</dc:identifier>
</item>
<item>
<title>International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384264/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>Despite abundant clinical innovation and burgeoning scientific investigation, pulmonary embolism (PE) has continued to pose a diagnostic and management challenge worldwide. Aging populations, patients living with a mounting number of chronic medical conditions, particularly cancer, and increasingly prevalent health care disparities herald a growing burden of PE. In the meantime, navigating expanding strategies for immediate and long-term anticoagulation, as well as advanced therapies, including...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1561-1577. doi: 10.1016/j.jacc.2024.07.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite abundant clinical innovation and burgeoning scientific investigation, pulmonary embolism (PE) has continued to pose a diagnostic and management challenge worldwide. Aging populations, patients living with a mounting number of chronic medical conditions, particularly cancer, and increasingly prevalent health care disparities herald a growing burden of PE. In the meantime, navigating expanding strategies for immediate and long-term anticoagulation, as well as advanced therapies, including catheter-based interventions for patients with more severe PE, has become progressively daunting. Accordingly, clinicians frequently turn to evidence-based clinical practice guidelines for diagnostic and management recommendations. However, numerous international guidelines, heterogeneity in recommendations, as well as areas of uncertainty or omission may leave the readers and clinicians without a clear management pathway. In this review of international PE guidelines, we highlight key areas of consistency, difference, and lack of recommendations (silence) with an emphasis on critical clinical and research needs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384264/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39384264</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.044>10.1016/j.jacc.2024.07.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384264</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Zuin</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Jennifer Ballard-Hernandez</dc:creator>
<dc:creator>Stefano Barco</dc:creator>
<dc:creator>Elisabeth M Battinelli</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>David Jimenez</dc:creator>
<dc:creator>Frederikus A Klok</dc:creator>
<dc:creator>Darsiya Krishnathasan</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:creator>Lisa Moores</dc:creator>
<dc:creator>Katelyn W Sylvester</dc:creator>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence</dc:title>
<dc:identifier>pmid:39384264</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.044</dc:identifier>
</item>
<item>
<title>Optimizing Outcomes in ST-Segment Elevation Myocardial Infarction: Is Prolonged Infusion of Bivalirudin Part of the Solution?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1525-1527. doi: 10.1016/j.jacc.2024.08.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39384263</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.049>10.1016/j.jacc.2024.08.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384263</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew A Cavender</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Outcomes in ST-Segment Elevation Myocardial Infarction: Is Prolonged Infusion of Bivalirudin Part of the Solution?</dc:title>
<dc:identifier>pmid:39384263</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.049</dc:identifier>
</item>
<item>
<title>Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384262/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1512-1524. doi: 10.1016/j.jacc.2024.07.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI) reduced all-cause mortality and bleeding without increasing reinfarction or stent thrombosis compared with heparin alone in patients with ST-segment elevation myocardial infarction (STEMI). These findings require external validation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine outcomes of bivalirudin vs heparin anticoagulation during PCI in STEMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed an individual-patient-data meta-analysis of all large randomized trials of bivalirudin vs heparin in STEMI patients undergoing primary PCI performed before BRIGHT-4. The primary endpoint was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Six trials randomizing 15,254 patients were included. Pooled across all regimens of bivalirudin and glycoprotein IIb/IIIa inhibitor (GPI) use, bivalirudin reduced 30-day all-cause mortality (2.5% vs 2.9%; adjusted OR: 0.78; 95% CI: 0.62-0.99), cardiac mortality (adjusted OR: 0.69; 95% CI: 0.54-0.88), and major bleeding (adjusted OR: 0.53; 95% CI: 0.44-0.64) but increased reinfarction (adjusted OR: 1.30; 95% CI: 1.02-1.65) and stent thrombosis (adjusted OR: 1.43; 95% CI: 1.05-1.93) compared with heparin. In 4 trials in which 6,244 patients were randomized to bivalirudin plus a high-dose post-PCI infusion vs heparin without planned GPI use (the BRIGHT-4 regimens), 30-day all-cause mortality occurred in 1.8% vs 2.9% of patients, respectively (adjusted OR: 0.74; 95% CI: 0.48-1.12), and bivalirudin reduced cardiac mortality (adjusted OR: 0.62; 95% CI: 0.39-0.97) and major bleeding (adjusted OR: 0.49; 95% CI: 0.35-0.70), with similar rates of reinfarction (adjusted OR: 0.89; 95% CI: 0.58-1.38) and stent thrombosis (adjusted OR: 0.80; 95% CI: 0.41-1.57).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384262/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39384262</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.045>10.1016/j.jacc.2024.07.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384262</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Rod H Stables</dc:creator>
<dc:creator>Enrico Frigoli</dc:creator>
<dc:creator>Stefan K James</dc:creator>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Patrick Goldstein</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Ghazaleh Mehdipoor</dc:creator>
<dc:creator>Aaron Crowley</dc:creator>
<dc:creator>Shmuel Chen</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Clayton Snyder</dc:creator>
<dc:creator>Zhipeng Zhou</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results</dc:title>
<dc:identifier>pmid:39384262</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.045</dc:identifier>
</item>
<item>
<title>Structure of TnsABCD transpososome reveals mechanisms of targeted DNA transposition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39383864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>Tn7-like transposons are characterized by their ability to insert specifically into host chromosomes. Recognition of the attachment (att) site by TnsD recruits the TnsABC proteins to form the transpososome and facilitate transposition. Although this pathway is well established, atomic-level structural insights of this process remain largely elusive. Here, we present the cryo-electron microscopy (cryo-EM) structures of the TnsC-TnsD-att DNA complex and the TnsABCD transpososome from the Tn7-like...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 8:S0092-8674(24)01071-7. doi: 10.1016/j.cell.2024.09.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tn7-like transposons are characterized by their ability to insert specifically into host chromosomes. Recognition of the attachment (att) site by TnsD recruits the TnsABC proteins to form the transpososome and facilitate transposition. Although this pathway is well established, atomic-level structural insights of this process remain largely elusive. Here, we present the cryo-electron microscopy (cryo-EM) structures of the TnsC-TnsD-att DNA complex and the TnsABCD transpososome from the Tn7-like transposon in Peltigera membranacea cyanobiont 210A, a type I-B CRISPR-associated transposon. Our structures reveal a striking bending of the att DNA, featured by the intercalation of an arginine side chain of TnsD into a CC/GG dinucleotide step. The TnsABCD transpososome structure reveals TnsA-TnsB interactions and demonstrates that TnsC not only recruits TnsAB but also directly participates in the transpososome assembly. These findings provide mechanistic insights into targeted DNA insertion by Tn7-like transposons, with implications for improving the precision and efficiency of their genome-editing applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39383864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39383864</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.023>10.1016/j.cell.2024.09.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39383864</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Shukun Wang</dc:creator>
<dc:creator>Romana Siddique</dc:creator>
<dc:creator>Mark C Hall</dc:creator>
<dc:creator>Phoebe A Rice</dc:creator>
<dc:creator>Leifu Chang</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure of TnsABCD transpososome reveals mechanisms of targeted DNA transposition</dc:title>
<dc:identifier>pmid:39383864</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.023</dc:identifier>
</item>
<item>
<title>A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39383863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 4:S0092-8674(24)01084-5. doi: 10.1016/j.cell.2024.09.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented cross-reactivity to all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently neutralizing SARS-CoV-2 variants since 2019, including the recent EG.5, BA.2.86, and JN.1. VIR-7229 tolerates extraordinary epitope variability, partly attributed to its high binding affinity, receptor molecular mimicry, and interactions with RBM backbone atoms. Consequently, VIR-7229 features a high barrier for selection of escape mutants, which are rare and associated with reduced viral fitness, underscoring its potential to be resilient to future viral evolution. VIR-7229 is a strong candidate to become a next-generation medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39383863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39383863</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.026>10.1016/j.cell.2024.09.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39383863</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura E Rosen</dc:creator>
<dc:creator>M Alejandra Tortorici</dc:creator>
<dc:creator>Anna De Marco</dc:creator>
<dc:creator>Dora Pinto</dc:creator>
<dc:creator>William B Foreman</dc:creator>
<dc:creator>Ashley L Taylor</dc:creator>
<dc:creator>Young-Jun Park</dc:creator>
<dc:creator>Dana Bohan</dc:creator>
<dc:creator>Tyson Rietz</dc:creator>
<dc:creator>John M Errico</dc:creator>
<dc:creator>Kevin Hauser</dc:creator>
<dc:creator>Ha V Dang</dc:creator>
<dc:creator>Justin W Chartron</dc:creator>
<dc:creator>Martina Giurdanella</dc:creator>
<dc:creator>Giuseppe Cusumano</dc:creator>
<dc:creator>Christian Saliba</dc:creator>
<dc:creator>Fabrizia Zatta</dc:creator>
<dc:creator>Kaitlin R Sprouse</dc:creator>
<dc:creator>Amin Addetia</dc:creator>
<dc:creator>Samantha K Zepeda</dc:creator>
<dc:creator>Jack Brown</dc:creator>
<dc:creator>Jimin Lee</dc:creator>
<dc:creator>Exequiel Dellota</dc:creator>
<dc:creator>Anushka Rajesh</dc:creator>
<dc:creator>Julia Noack</dc:creator>
<dc:creator>Qiqing Tao</dc:creator>
<dc:creator>Yvonne DaCosta</dc:creator>
<dc:creator>Brian Tsu</dc:creator>
<dc:creator>Rima Acosta</dc:creator>
<dc:creator>Sambhavi Subramanian</dc:creator>
<dc:creator>Guilherme Dias de Melo</dc:creator>
<dc:creator>Lauriane Kergoat</dc:creator>
<dc:creator>Ivy Zhang</dc:creator>
<dc:creator>Zhuoming Liu</dc:creator>
<dc:creator>Barbara Guarino</dc:creator>
<dc:creator>Michael A Schmid</dc:creator>
<dc:creator>Gretja Schnell</dc:creator>
<dc:creator>Jessica L Miller</dc:creator>
<dc:creator>Florian A Lempp</dc:creator>
<dc:creator>Nadine Czudnochowski</dc:creator>
<dc:creator>Elisabetta Cameroni</dc:creator>
<dc:creator>Sean P J Whelan</dc:creator>
<dc:creator>Hervé Bourhy</dc:creator>
<dc:creator>Lisa A Purcell</dc:creator>
<dc:creator>Fabio Benigni</dc:creator>
<dc:creator>Julia di Iulio</dc:creator>
<dc:creator>Matteo Samuele Pizzuto</dc:creator>
<dc:creator>Antonio Lanzavecchia</dc:creator>
<dc:creator>Amalio Telenti</dc:creator>
<dc:creator>Gyorgy Snell</dc:creator>
<dc:creator>Davide Corti</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:creator>Tyler N Starr</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification</dc:title>
<dc:identifier>pmid:39383863</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.026</dc:identifier>
</item>
<item>
<title>Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39383862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>Aberrant expression of repeat RNAs in pancreatic ductal adenocarcinoma (PDAC) mimics viral-like responses with implications on tumor cell state and the response of the surrounding microenvironment. To better understand the relationship of repeat RNAs in human PDAC, we performed spatial molecular imaging at single-cell resolution in 46 primary tumors, revealing correlations of high repeat RNA expression with alterations in epithelial state in PDAC cells and myofibroblast phenotype in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 1:S0092-8674(24)01072-9. doi: 10.1016/j.cell.2024.09.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Aberrant expression of repeat RNAs in pancreatic ductal adenocarcinoma (PDAC) mimics viral-like responses with implications on tumor cell state and the response of the surrounding microenvironment. To better understand the relationship of repeat RNAs in human PDAC, we performed spatial molecular imaging at single-cell resolution in 46 primary tumors, revealing correlations of high repeat RNA expression with alterations in epithelial state in PDAC cells and myofibroblast phenotype in cancer-associated fibroblasts (CAFs). This loss of cellular identity is observed with dosing of extracellular vesicles (EVs) and individual repeat RNAs of PDAC and CAF cell culture models pointing to cell-cell intercommunication of these viral-like elements. Differences in PDAC and CAF responses are driven by distinct innate immune signaling through interferon regulatory factor 3 (IRF3). The cell-context-specific viral-like responses to repeat RNAs provide a mechanism for modulation of cellular plasticity in diverse cell types in the PDAC microenvironment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39383862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39383862</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.024>10.1016/j.cell.2024.09.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39383862</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Eunae You</dc:creator>
<dc:creator>Patrick Danaher</dc:creator>
<dc:creator>Chenyue Lu</dc:creator>
<dc:creator>Siyu Sun</dc:creator>
<dc:creator>Luli Zou</dc:creator>
<dc:creator>Ildiko E Phillips</dc:creator>
<dc:creator>Alexandra S Rojas</dc:creator>
<dc:creator>Natalie I Ho</dc:creator>
<dc:creator>Yuhui Song</dc:creator>
<dc:creator>Michael J Raabe</dc:creator>
<dc:creator>Katherine H Xu</dc:creator>
<dc:creator>Peter M Richieri</dc:creator>
<dc:creator>Hao Li</dc:creator>
<dc:creator>Natalie Aston</dc:creator>
<dc:creator>Rebecca L Porter</dc:creator>
<dc:creator>Bidish K Patel</dc:creator>
<dc:creator>Linda T Nieman</dc:creator>
<dc:creator>Nathan Schurman</dc:creator>
<dc:creator>Briana M Hudson</dc:creator>
<dc:creator>Khrystyna North</dc:creator>
<dc:creator>Sarah E Church</dc:creator>
<dc:creator>Vikram Deshpande</dc:creator>
<dc:creator>Andrew S Liss</dc:creator>
<dc:creator>Tae K Kim</dc:creator>
<dc:creator>Yi Cui</dc:creator>
<dc:creator>Youngmi Kim</dc:creator>
<dc:creator>Benjamin D Greenbaum</dc:creator>
<dc:creator>Martin J Aryee</dc:creator>
<dc:creator>David T Ting</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer</dc:title>
<dc:identifier>pmid:39383862</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.024</dc:identifier>
</item>
<item>
<title>Error in Figure 1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3703. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39382877</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3703>10.1001/jamacardio.2024.3703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382877</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure 1</dc:title>
<dc:identifier>pmid:39382877</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3703</dc:identifier>
</item>
<item>
<title>Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: Results of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT. However, an increased risk of MACCE cannot be excluded, and 3 months of DAPT followed by potent P2Y12 inhibitor monotherapy was ranked as the best option to reduce MACCE. Because...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3216. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To analyze the efficacy and safety of DAPT strategies in patients with ACS using a bayesian network meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: MEDLINE, Embase, Cochrane, and LILACS databases were searched from inception to April 8, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Randomized clinical trials (RCTs) comparing DAPT duration strategies in patients with ACS undergoing PCI were selected. Short-term strategies (1 month of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by aspirin, and 6 months of DAPT followed by aspirin) were compared with conventional 12 months of DAPT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: This systematic review and network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The risk ratio (RR) with a 95% credible interval (CrI) was calculated within a bayesian random-effects network meta-analysis. Treatments were ranked using surface under the cumulative ranking (SUCRA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary efficacy end point was major adverse cardiac and cerebrovascular events (MACCE); the primary safety end point was major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 15 RCTs randomizing 35 326 patients (mean [SD] age, 63.1 [11.1] years; 26 954 male [76.3%]; 11 339 STEMI [32.1%]) with ACS were included. A total of 24 797 patients (70.2%) received potent P2Y12 inhibitors (ticagrelor or prasugrel). Compared with 12 months of DAPT, 1 month of DAPT followed by P2Y12 inhibitors reduced major bleeding (RR, 0.47; 95% CrI, 0.26-0.74) with no difference in MACCE (RR, 1.00; 95% CrI, 0.70-1.41). No significant differences were observed in MACCE incidence between strategies, although CrIs were wide. SUCRA ranked 1 month of DAPT followed by P2Y12 inhibitors as the best for reducing major bleeding and 3 months of DAPT followed by P2Y12 inhibitors as optimal for reducing MACCE (RR, 0.85; 95% CrI, 0.56-1.21).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: Results of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT. However, an increased risk of MACCE cannot be excluded, and 3 months of DAPT followed by potent P2Y12 inhibitor monotherapy was ranked as the best option to reduce MACCE. Because most patients receiving P2Y12 inhibitor monotherapy were taking ticagrelor, the safety of stopping aspirin in those taking clopidogrel remains unclear.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39382876</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3216>10.1001/jamacardio.2024.3216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382876</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro E P Carvalho</dc:creator>
<dc:creator>Douglas M Gewehr</dc:creator>
<dc:creator>Bruno R Nascimento</dc:creator>
<dc:creator>Lara Melo</dc:creator>
<dc:creator>Giullia Burkhardt</dc:creator>
<dc:creator>André Rivera</dc:creator>
<dc:creator>Marcelo A P Braga</dc:creator>
<dc:creator>Patricia O Guimarães</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Shao-Liang Chen</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis</dc:title>
<dc:identifier>pmid:39382876</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3216</dc:identifier>
</item>
<item>
<title>Ventricular Septal Rupture After ST-Segment Elevation Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3308. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39382857</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3308>10.1001/jamacardio.2024.3308</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382857</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alex Melot</dc:creator>
<dc:creator>Pierre Groussin</dc:creator>
<dc:creator>Raphaël P Martins</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Ventricular Septal Rupture After ST-Segment Elevation Myocardial Infarction</dc:title>
<dc:identifier>pmid:39382857</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3308</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3241. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Historically, women with aortic stenosis have experienced worse outcomes and inadequate recognition compared to men, being both underdiagnosed and undertreated, while also facing underrepresentation in clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether women with small aortic annuli undergoing transcatheter aortic valve replacement have better clinical and hemodynamic outcomes with a self-expanding valve (SEV) or balloon-expandable valve (BEV).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, PARTICIPANTS: The Small Annuli Randomized to Evolut or SAPIEN Trial (SMART) was a large-scale randomized clinical trial focusing on patients with small aortic annuli undergoing transcatheter aortic valve replacement, randomized to receive SEVs or BEVs and included 716 patients treated at 83 centers in Canada, Europe, Israel, and the US from April 2021 to October 2022. This prespecified secondary analysis reports clinical and hemodynamic findings for all 621 women enrolled in SMART. Data for this report were analyzed from February to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Transcatheter aortic valve replacement with an SEV or a BEV.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The composite coprimary clinical end point comprised death, disabling stroke, or heart failure-related rehospitalization. The coprimary valve function end point was the incidence of bioprosthetic valve dysfunction, both assessed through 12 months. Secondary end points included the incidence of moderate or severe prosthesis-patient mismatch.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 621 women (mean [SD] age, 80.2 [6.2] years; 312 randomized to the SEV group and 309 to the BEV group) were included in the present analysis. At 12 months, there were no significant differences in the coprimary clinical end point between the SEV and BEV groups (9.4% vs 11.8%, absolute risk difference -2.3%; 95% CI -7.2 to 2.5, P = .35). However, SEV implantation was associated with less bioprosthetic valve dysfunction (8.4% vs 41.8%; absolute risk difference, -33.4%; 95% CI, -40.4 to -26.4; P &lt; .001). SEV implantation resulted in lower aortic valve gradients and larger effective orifice areas at 30 days and 12 months and less mild or greater aortic regurgitation at 12 months compared to BEV implantation. Prosthesis-patient mismatch was significantly lower with SEVs, regardless of the definition used and adjustment for body mass index. Use of SEVs was associated with better quality of life outcomes as assessed by the Valve Academic Research Consortium-3 ordinal quality of life measure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04722250.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39382856</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3241>10.1001/jamacardio.2024.3241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382856</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Didier Tchétché</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Daniel J Blackman</dc:creator>
<dc:creator>Ramzi F Khalil</dc:creator>
<dc:creator>Helge Möllmann</dc:creator>
<dc:creator>Mohamed Abdel-Wahab</dc:creator>
<dc:creator>Walid Ben Ali</dc:creator>
<dc:creator>Paul D Mahoney</dc:creator>
<dc:creator>Hendrik Ruge</dc:creator>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:creator>Lang Lin</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Isida Byku</dc:creator>
<dc:creator>Mayra Guerrero</dc:creator>
<dc:creator>Linda D Gillam</dc:creator>
<dc:creator>Anna Sonia Petronio</dc:creator>
<dc:creator>Guilherme F Attizzani</dc:creator>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Toby Rogers</dc:creator>
<dc:creator>Joshua D Rovin</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Stewart Benton</dc:creator>
<dc:creator>Blake Gardner</dc:creator>
<dc:creator>Ratnasari Padang</dc:creator>
<dc:creator>Andrew D Althouse</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39382856</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3241</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382619/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 1;9(10):866. doi: 10.1001/jamacardio.2023.3679.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382619/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39382619</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3679>10.1001/jamacardio.2023.3679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382619</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39382619</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3679</dc:identifier>
</item>
<item>
<title>A core microbiome signature as an indicator of health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378879/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>The gut microbiota is crucial for human health, functioning as a complex adaptive system akin to a vital organ. To identify core health-relevant gut microbes, we followed the systems biology tenet that stable relationships signify core components. By analyzing metagenomic datasets from a high-fiber dietary intervention in type 2 diabetes and 26 case-control studies across 15 diseases, we identified a set of stably correlated genome pairs within co-abundance networks perturbed by dietary...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 27:S0092-8674(24)01038-9. doi: 10.1016/j.cell.2024.09.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gut microbiota is crucial for human health, functioning as a complex adaptive system akin to a vital organ. To identify core health-relevant gut microbes, we followed the systems biology tenet that stable relationships signify core components. By analyzing metagenomic datasets from a high-fiber dietary intervention in type 2 diabetes and 26 case-control studies across 15 diseases, we identified a set of stably correlated genome pairs within co-abundance networks perturbed by dietary interventions and diseases. These genomes formed a "two competing guilds" (TCGs) model, with one guild specialized in fiber fermentation and butyrate production and the other characterized by virulence and antibiotic resistance. Our random forest models successfully distinguished cases from controls across multiple diseases and predicted immunotherapy outcomes through the use of these genomes. Our guild-based approach, which is genome specific, database independent, and interaction focused, identifies a core microbiome signature that serves as a holistic health indicator and a potential common target for health enhancement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378879/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378879</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.019>10.1016/j.cell.2024.09.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378879</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Guojun Wu</dc:creator>
<dc:creator>Ting Xu</dc:creator>
<dc:creator>Naisi Zhao</dc:creator>
<dc:creator>Yan Y Lam</dc:creator>
<dc:creator>Xiaoying Ding</dc:creator>
<dc:creator>Dongqin Wei</dc:creator>
<dc:creator>Jian Fan</dc:creator>
<dc:creator>Yajuan Shi</dc:creator>
<dc:creator>Xiaofeng Li</dc:creator>
<dc:creator>Mi Li</dc:creator>
<dc:creator>Shenjie Ji</dc:creator>
<dc:creator>Xuejiao Wang</dc:creator>
<dc:creator>Huaqing Fu</dc:creator>
<dc:creator>Feng Zhang</dc:creator>
<dc:creator>Yu Shi</dc:creator>
<dc:creator>Chenhong Zhang</dc:creator>
<dc:creator>Yongde Peng</dc:creator>
<dc:creator>Liping Zhao</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A core microbiome signature as an indicator of health</dc:title>
<dc:identifier>pmid:39378879</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.019</dc:identifier>
</item>
<item>
<title>Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378878/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>Breast disseminated cancer cells (DCCs) can remain dormant in the lungs for extended periods, but the mechanisms limiting their expansion are not well understood. Research indicates that tissue-resident alveolar macrophages suppress breast cancer metastasis in lung alveoli by inducing dormancy. Through ligand-receptor mapping and intravital imaging, it was found that alveolar macrophages express transforming growth factor (TGF)-β2. This expression, along with persistent macrophage-cancer cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 4:S0092-8674(24)01034-1. doi: 10.1016/j.cell.2024.09.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Breast disseminated cancer cells (DCCs) can remain dormant in the lungs for extended periods, but the mechanisms limiting their expansion are not well understood. Research indicates that tissue-resident alveolar macrophages suppress breast cancer metastasis in lung alveoli by inducing dormancy. Through ligand-receptor mapping and intravital imaging, it was found that alveolar macrophages express transforming growth factor (TGF)-β2. This expression, along with persistent macrophage-cancer cell interactions via the TGF-βRIII receptor, maintains cancer cells in a dormant state. Depleting alveolar macrophages or losing the TGF-β2 receptor in cancer cells triggers metastatic awakening. Aggressive breast cancer cells are either suppressed by alveolar macrophages or evade this suppression by avoiding interaction and downregulating the TGF-β2 receptor. Restoring TGF-βRIII in aggressive cells reinstates TGF-β2-mediated macrophage growth suppression. Thus, alveolar macrophages act as a metastasis immune barrier, and downregulation of TGF-β2 signaling allows cancer cells to overcome macrophage-mediated growth suppression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378878/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378878</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.016>10.1016/j.cell.2024.09.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378878</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Erica Dalla</dc:creator>
<dc:creator>Michael Papanicolaou</dc:creator>
<dc:creator>Matthew D Park</dc:creator>
<dc:creator>Nicole Barth</dc:creator>
<dc:creator>Rui Hou</dc:creator>
<dc:creator>Deisy Segura-Villalobos</dc:creator>
<dc:creator>Luis Valencia Salazar</dc:creator>
<dc:creator>Dan Sun</dc:creator>
<dc:creator>Alistair R R Forrest</dc:creator>
<dc:creator>Maria Casanova-Acebes</dc:creator>
<dc:creator>David Entenberg</dc:creator>
<dc:creator>Miriam Merad</dc:creator>
<dc:creator>Julio A Aguirre-Ghiso</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis</dc:title>
<dc:identifier>pmid:39378878</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.016</dc:identifier>
</item>
<item>
<title>Refining the stratification of sudden cardiac death risk after myocardial infarction-beyond ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378271/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 8:ehae272. doi: 10.1093/eurheartj/ehae272. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378271/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378271</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae272>10.1093/eurheartj/ehae272</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378271</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ezimamaka C Ajufo</dc:creator>
<dc:creator>Usha B Tedrow</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Refining the stratification of sudden cardiac death risk after myocardial infarction-beyond ejection fraction</dc:title>
<dc:identifier>pmid:39378271</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae272</dc:identifier>
</item>
<item>
<title>Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: More accurate risk stratification for sudden cardiac death and identification of low-risk individuals with severely reduced LVEF or of high-risk individuals with preserved LVEF was not feasible, neither using LVEF nor using other predictors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 8:ehae326. doi: 10.1093/eurheartj/ehae326. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Risk stratification of sudden cardiac death after myocardial infarction and prevention by defibrillator rely on left ventricular ejection fraction (LVEF). Improved risk stratification across the whole LVEF range is required for decision-making on defibrillator implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The analysis pooled 20 data sets with 140 204 post-myocardial infarction patients containing information on demographics, medical history, clinical characteristics, biomarkers, electrocardiography, echocardiography, and cardiac magnetic resonance imaging. Separate analyses were performed in patients (i) carrying a primary prevention cardioverter-defibrillator with LVEF ≤ 35% [implantable cardioverter-defibrillator (ICD) patients], (ii) without cardioverter-defibrillator with LVEF ≤ 35% (non-ICD patients ≤ 35%), and (iii) without cardioverter-defibrillator with LVEF >; 35% (non-ICD patients >;35%). Primary outcome was sudden cardiac death or, in defibrillator carriers, appropriate defibrillator therapy. Using a competing risk framework and systematic internal-external cross-validation, a model using LVEF only, a multivariable flexible parametric survival model, and a multivariable random forest survival model were developed and externally validated. Predictive performance was assessed by random effect meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were 1326 primary outcomes in 7543 ICD patients, 1193 in 25 058 non-ICD patients ≤35%, and 1567 in 107 603 non-ICD patients >;35% during mean follow-up of 30.0, 46.5, and 57.6 months, respectively. In these three subgroups, LVEF poorly predicted sudden cardiac death (c-statistics between 0.50 and 0.56). Considering additional parameters did not improve calibration and discrimination, and model generalizability was poor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: More accurate risk stratification for sudden cardiac death and identification of low-risk individuals with severely reduced LVEF or of high-risk individuals with preserved LVEF was not feasible, neither using LVEF nor using other predictors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378245</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae326>10.1093/eurheartj/ehae326</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378245</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Niels Peek</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Artur Akbarov</dc:creator>
<dc:creator>Jan G P Tijssen</dc:creator>
<dc:creator>David A Jenkins</dc:creator>
<dc:creator>Zoher Kapacee</dc:creator>
<dc:creator>Le Mai Parkes</dc:creator>
<dc:creator>Rob J van der Geest</dc:creator>
<dc:creator>Enrico Longato</dc:creator>
<dc:creator>Daniel Sprague</dc:creator>
<dc:creator>Youssef Taleb</dc:creator>
<dc:creator>Marcus Ong</dc:creator>
<dc:creator>Christopher A Miller</dc:creator>
<dc:creator>Alireza Sepehri Shamloo</dc:creator>
<dc:creator>Christine Albert</dc:creator>
<dc:creator>Petra Barthel</dc:creator>
<dc:creator>Serge Boveda</dc:creator>
<dc:creator>Frieder Braunschweig</dc:creator>
<dc:creator>Jens Brock Johansen</dc:creator>
<dc:creator>Nancy Cook</dc:creator>
<dc:creator>Christian de Chillou</dc:creator>
<dc:creator>Petra Elders</dc:creator>
<dc:creator>Jonas Faxén</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Laura Fusini</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:creator>Jiri Jarkovsky</dc:creator>
<dc:creator>Xavier Jouven</dc:creator>
<dc:creator>Juhani Junttila</dc:creator>
<dc:creator>Josef Kautzner</dc:creator>
<dc:creator>Antti Kiviniemi</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:creator>Christophe Leclercq</dc:creator>
<dc:creator>Daniel C Lee</dc:creator>
<dc:creator>Jill Leigh</dc:creator>
<dc:creator>Radosław Lenarczyk</dc:creator>
<dc:creator>Francisco Leyva</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:creator>Andrea Manca</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Ursula Marschall</dc:creator>
<dc:creator>Jose Luis Merino</dc:creator>
<dc:creator>Lluis Mont</dc:creator>
<dc:creator>Jens Cosedis Nielsen</dc:creator>
<dc:creator>Thomas Olsen</dc:creator>
<dc:creator>Julie Pester</dc:creator>
<dc:creator>Gianluca Pontone</dc:creator>
<dc:creator>Ivo Roca</dc:creator>
<dc:creator>Georg Schmidt</dc:creator>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:creator>Christian Sticherling</dc:creator>
<dc:creator>Mahmoud Suleiman</dc:creator>
<dc:creator>Milos Taborsky</dc:creator>
<dc:creator>Hanno L Tan</dc:creator>
<dc:creator>Jacob Tfelt-Hansen</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Gordon F Tomaselli</dc:creator>
<dc:creator>Tom Verstraelen</dc:creator>
<dc:creator>Manickavasagar Vinayagamoorthy</dc:creator>
<dc:creator>Kevin Kris Warnakula Olesen</dc:creator>
<dc:creator>Arthur Wilde</dc:creator>
<dc:creator>Rik Willems</dc:creator>
<dc:creator>Katherine C Wu</dc:creator>
<dc:creator>Markus Zabel</dc:creator>
<dc:creator>Glen P Martin</dc:creator>
<dc:creator>Nikolaos Dagres</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts</dc:title>
<dc:identifier>pmid:39378245</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae326</dc:identifier>
</item>
<item>
<title>Non-vitamin K oral anticoagulants in valvular heart disease before surgery: a tale of bridging vs. no bridging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 8:ehae615. doi: 10.1093/eurheartj/ehae615. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378243</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae615>10.1093/eurheartj/ehae615</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378243</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:creator>Hugo Ten Cate</dc:creator>
<dc:creator>Vittorio Pengo</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-vitamin K oral anticoagulants in valvular heart disease before surgery: a tale of bridging vs. no bridging</dc:title>
<dc:identifier>pmid:39378243</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae615</dc:identifier>
</item>
<item>
<title>Cardiac arrhythmias: the growing role of autoantibodies in diagnosis and treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378151/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 8:ehae648. doi: 10.1093/eurheartj/ehae648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378151/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378151</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae648>10.1093/eurheartj/ehae648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378151</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Funsho E Fakuade</dc:creator>
<dc:creator>Jana Grune</dc:creator>
<dc:creator>Niels Voigt</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac arrhythmias: the growing role of autoantibodies in diagnosis and treatment</dc:title>
<dc:identifier>pmid:39378151</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae648</dc:identifier>
</item>
<item>
<title>Traboulsi syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39378150/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241010181013&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 8:ehae633. doi: 10.1093/eurheartj/ehae633. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39378150/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241010181013&v=2.18.0.post9+e462414">39378150</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae633>10.1093/eurheartj/ehae633</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39378150</guid>
<pubDate>Tue, 08 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel de Castro</dc:creator>
<dc:creator>David Pujol-Pocull</dc:creator>
<dc:creator>Fernando Domínguez</dc:creator>
<dc:date>2024-10-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Traboulsi syndrome</dc:title>
<dc:identifier>pmid:39378150</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae633</dc:identifier>
</item>





























</channel>
</rss>